BSECompany Update2d ago · 10 Aug 2026, 06:38 pm

Pursuant to Regulation 32(6) of SEBI (LODR) Regulations 2015, read with Regulation 173A of SEBI (ICDR) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilisation ....

Wockhardt Ltd · 532300

✦ AI SummaryResults

Wockhardt Ltd has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of proceeds from its Qualified Institutional Placement (QIP) in November 2024. The report confirms that there has been no deviation in the utilization of issue proceeds from the objects as stated in the Placement Document.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

Attachments (1)

📄

5bba33d1-85fc-48d0-811f-db703758cfd4.pdf

pdf

Download →
View document text
Ref. No.: WOCK/SEC/SE/2026-27/033 August 10, 2026 BSE Limited National Stock Exchange of India Limited Corporate Relations Department Exchange Plaza P J Towers, Dalal Street Bandra Kurla Complex, Bandra (E), Mumbai - 400 001 Mumbai - 400 051 Scrip Code: 532300 NSE Symbol: WOCKPHARMA Sub: Monitoring Agency Report for the quarter ended June 30, 2026 Dear Sir/Madam, Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Regulation 173A of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, please find enclosed Monitoring Agency Report towards utilization of proceeds of Qualified Institutions Placement (“QIP”) for the quarter ended June 30, 2026, issued by CRISIL Ratings Limited, duly reviewed and taken on record by the Board of Directors & Audit Committee of the Company. Further, we hereby confirm that there has been no deviation in the utilization of Issue proceeds from the objects as stated in the Placement Document dated November 11, 2024. Kindly take the above information on record. Thanking you, For Wockhardt Limited Rashmi Mamtura Company Secretary Monitoring Agency Report Wockhardt Limited for the quarter ended June 30, 2026 CRL/MAR/WOCLIM/2026-27/1972 August 10, 2026 Wockhardt Limited Wockhardt Research Centre, D – 4, MIDC, Chikalthana, Aurangabad 431 006, Maharashtra, India Dear Sir, Monitoring Agency Report for the quarter ended June 30, 2026 - in relation to the Qualified Institutional Placement (“QIP”) of Wockhardt Limited (“the Company”) Pursuant to Regulation 173A of SEBI (lssue of Capital and Disclosure Requirements) Regulations, 2018 (“SEBI ICDR Regulations”) and Monitoring Agency Agreement dated October 28, 2024, enclosed herewith the Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of QIP for the quarter ended June 30, 2026. Request you to kindly take the same on records. Thanking you, For and on behalf of Crisil Ratings Limited Shounak Chakravarty Director, Ratings (LCG) Report of the Monitoring Agency (MA) Name of the issuer: Wockhardt Limited For quarter ended: June 30, 2026 Name of the Monitoring Agency: Crisil Ratings Limited (a) Deviation from the objects: No (b) Range of Deviation: Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title “Comments of the Board of Directors”, that shall be captured by the Issuer’s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer’s Management/Board. Signature: Name and designation of the Authorized Signatory: Shounak Chakravarty Designation of Authorized person/Signing Authority: Director, Ratings (LCG) 1) Issuer Details: Name of the issuer: Wockhardt Limited Names of the promoter: a. Mr. Habil F Khorakiwala b. Themisto Trustee Company Private Limited Industry/sector to which it belongs: Pharmaceuticals 2) Issue Details Issue Period: November 06, 2024, to November 11, 2024 Type of issue (public/rights): Qualified Institutional Placement (QIP) Type of specified securities: Equity Shares QIP Grading, if any: NA Issue size: Gross proceeds: Rs 1,000.00 crores Net proceeds: Rs 977.79 crores*# *Crisil Ratings shall be monitoring the net proceeds. # During the quarter ended June 30, 2025, net proceeds have been revised from Rs 973.97 crores to Rs 977.79 crores, on account of actual issue expenses being lower than estimated as disclosed in the Offer Document, by Rs 3.82 crores and the same has been adjusted with Object 3: General Corporate Purposes. 3) Details of the arrangement made to ensure the monitoring of issue proceeds: Source of information/ certifications Comments of Comments considered by the of the Particulars Reply Monitoring Agency Monitoring Board of for preparation of Agency Directors report Management undertaking, Peer Reviewed Independent Whether all utilization is as per the disclosures No Yes Chartered Accountant No Comments in the Offer Document? Comments Certificate^, Placement Document, Bank Statements Whether shareholder approval has been obtained in case of material deviations from No NA No Comments expenditures disclosed in the Offer Comments Document? Whether the means of finance for the disclosed No No No Comments objects of the issue has changed? Comments Source of information/ certifications Comments of Comments considered by the of the Particulars Reply Monitoring Agency Monitoring Board of for preparation of Agency Directors report Is there any major deviation observed over the No NA No Comments earlier monitoring agency reports? Comments Whether all Government/statutory approvals No NA No Comments related to the object(s) have been obtained? Comments Management Undertaking* Whether all arrangements pertaining to technical assistance/collaboration are in NA No Comments Comments operation? Are there any favorable events improving the No No No Comments viability of these object(s)? Comments Are there any unfavorable events affecting the No No No Comments viability of the object(s)? Comments Is there any other relevant information that may materially affect the decision making of No No Comments Comments the investors? NA represents Not Applicable ^Certificate dated August 05, 2026, issued by M/s Harshil Patel & Co., Chartered Accountants (Firm Registration Number: 148237W), Peer-reviewed Independent Chartered Accountant. *The Monitoring Agency has relied solely on the management undertaking as the Peer Reviewed Independent Chartered Accountant has not expressed an opinion on these. 4) Details of object(s) to be monitored: i. Cost of the object(s): Source of Original Comments of the Board of Directors information/ cost Revised Comment of Particulars certification (as per the Sr. Cost the Reason of Proposed of firm Item considered by Offer No. (Rs in Monitoring Cost financing arrangement Head MA for Document) crore) agency revision option s preparation of (Rs in made report crore) Repayment and / or pre – payment, in full or part, of 1 500.00 500.00 No revision No Comments certain borrowings availed by the Company Management undertaking, Independent Funding of capital Chartered expenditure, Account [Showing first 8,000 characters — download PDF for full document]